Esperion Therapeutics, Inc. (ESPR)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$156.2M
Cash & Equivalents
$27.7M
Quarterly Burn Rate
17 mo
Est. Cash Runway
$819M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT06300450 Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not... OTHER Recruiting 400
NCT05103254 Bempedoic Acid Pregnancy Surveillance Program OTHER Recruiting 20

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ESPR.

SEC EDGAR Filings

All SEC filings for Esperion Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.